Trustpair, a platform for automated vendor payment fraud prevention, has partnered with Certa, a leader in third-party risk management tools, to integrate fraud prevention and compliance capabilities for enterprise procurement teams. The integration allows Certa customers to access Trustpair's automated bank account ownership verification directly within Certa's platform. The partnership addresses growing concerns around AI-powered fraud and regulatory scrutiny. According to Trustpair's 2026 Fraud Report, 71% of US companies reported increased AI-powered fraud attempts over the past 12 months. The integration enables organisations to verify vendor banking information and assess fraud risk within existing third-party onboarding and monitoring workflows. The combined solution provides real-time bank account verification and risk evaluations, allowing procurement and compliance teams to manage vendor relationships from onboarding through payment without switching tools.

👩‍🍳 How we use AI at Tech in Asia, thoughtfully and responsibly.🧔‍♂️ A friendly human may check it before it goes live. More news hereThe US Food and Drug Administration (FDA) has introduced a new generative AI tool named Elsa to boost operational efficiency.Elsa assists employees with tasks like document analysis, data management, clinical protocol reviews, and adverse event summarization.It also supports safety assessments, inspection targeting, and can generate code for nonclinical database development.Elsa runs in a secure GovCloud environment, protecting sensitive internal data. It does not process or train on data from regulated industries, maintaining confidentiality.The rollout follows a pilot with FDA scientific reviewers and is ahead of the agency’s June 30, 2025 timeline.The FDA plans to expand Elsa’s capabilities with more AI functionalities over time.🔗 Source: US Food and Drug Administration🧠 Food for thought1️⃣ Government agencies are rapidly adopting AI for regulatory efficiencyThe FDA’s launch of Elsa reflects a broader trend of government agencies leveraging AI to transform regulatory operations and improve public services.Transportation departments are using AI for traffic management and predictive maintenance, while law enforcement agencies deploy it for digital forensics to enhance public safety 1.Regulatory agencies are finding AI particularly valuable for automating administrative tasks, with the ability to analyze stakeholder input and streamline regulatory processes, saving both time and resources 2.The Defense Department’s GAMECHANGER tool centralizes regulatory guidance to improve coordination, demonstrating how AI can address the complexity of government operations across different sectors 3.These implementations show that FDA’s move is part of a government-wide shift toward AI adoption, with agencies increasingly recognizing AI’s potential to reduce manual effort while enhancing accuracy in regulatory functions.2️⃣ AI compliance and security features reflect evolving regulatory requirementsFDA’s emphasis on Elsa being built within a “high-security GovCloud environment” addresses growing concerns about data protection in government AI implementations.Organizations implementing AI compliance tools are increasingly focusing on automated workflows and real-time monitoring dashboards to ensure adherence to regulations, as seen in the finance and healthcare sectors 4.The integration of AI in compliance processes has been shown to enhance operational efficiency while reducing the risk of human error, which is critical for an agency handling sensitive health data 5.FDA’s approach mirrors best practices identified in the industry, where predictive analytics are used to forecast potential compliance issues before they occur, potentially helping the agency stay ahead of emerging risks 5.By ensuring all information remains within the agency and preventing training on industry-submitted data, the FDA is addressing key transparency and data governance concerns that experts have identified as essential for responsible AI deployment 6.3️⃣ FDA’s AI implementation connects to broader healthcare transformation trendsThe FDA’s adoption of AI for clinical protocol reviews and scientific evaluations parallels the healthcare industry’s increasing use of AI to improve diagnostic accuracy and treatment decisions.Systems like LumineticsCore, the first FDA-approved AI system for diabetic retinopathy screening, demonstrate how AI can enhance clinical workflows by enabling non-specialists to perform complex diagnostic tasks 7.FDA’s emphasis on using AI to “identify high-priority inspection targets” connects to the broader trend of using AI for risk assessment, where algorithms analyze diverse datasets to identify emerging risks and recommend mitigation strategies 5.This adoption suggests FDA is positioning itself to better understand and regulate the very AI technologies it oversees in healthcare, potentially improving its ability to evaluate the growing number of AI-enabled medical devices seeking approval.Recent FDA developments